Journal of translational medicine · 2026
Mast cell-specific receptor MrgprB2 selectively mediates oxaliplatin-induced neuropathic pain.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guan Leo C, Luo Zhaoli, Kothari Ruchita, Liu Meilian, Wan Jieru, Uniyal Ankit, Guan Annie Y, Lin Qing, Dong Xinzhong, Liu Jing
Аннотация
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) causes debilitating pain that limits anticancer treatment, yet effective therapies remain limited. Mast cells (MCs) regulate neuroimmune signaling implicated in CIPN, but their receptor-specific contributions remain poorly understood. In mice, oxaliplatin and paclitaxel produce robust mechanical and cold hypersensitivities that mirror CIPN pain. Mas-related G-protein-coupled receptor B2 (MrgprB2) and its human orthologue MrgprX2 are MC-restricted receptors that mediate non-IgE-mediated activation. However, whether MrgprB2 signaling differently contributes to oxaliplatin- versus paclitaxel-induced CIPN pain remains unclear.
METHODS: We employed a comparative mechanistic approach using wild-type (WT) and MrgprB2 knockout (KO) mice to define receptor-specific contributions to oxaliplatin- versus paclitaxel-induced CIPN pain. Behavioral assessments of mechanical and cold hypersensitivity were integrated with histological profiling of MC recruitment and mediator profiles. Genetic findings were validated pharmacologically with osthole, a natural MrgprB2/X2 antagonist.
RESULTS: Both oxaliplatin and paclitaxel induced cutaneous MC accumulation in the hindpaw of WT mice, but they triggered distinct MC mediator-release profiles in vivo: oxaliplatin preferentially elevated tryptase, while paclitaxel was associated with greater histamine enrichment. Yet, neither drug directly activate MCs in vitro, as indicated by unchanged β-hexosaminidase release and calcium signaling. Importantly, MrgprB2 KO selectively attenuated oxaliplatin-induced tryptase upregulation and mechanical and cold hypersensitivity in vivo, without affecting paclitaxel-induced histamine changes or pain behavior. Consistently, with these genetic results, osthole selectively attenuated oxaliplatin-induced pain, but not paclitaxel-induced pain in WT mice.
CONCLUSIONS: These findings support a mechanistic dichotomy in CIPN pain, indicating that MrgprB2 contributes selectively to oxaliplatin-induced, but not paclitaxel-induced, CIPN in mice. More broadly, they suggest that CIPN involves mechanistically distinct neuroimmune states depending on the chemotherapeutic class and highlight MrgprB2/X2 as a drug class-selective target for platinum-induced CIPN pain treatment.
METHODS: We employed a comparative mechanistic approach using wild-type (WT) and MrgprB2 knockout (KO) mice to define receptor-specific contributions to oxaliplatin- versus paclitaxel-induced CIPN pain. Behavioral assessments of mechanical and cold hypersensitivity were integrated with histological profiling of MC recruitment and mediator profiles. Genetic findings were validated pharmacologically with osthole, a natural MrgprB2/X2 antagonist.
RESULTS: Both oxaliplatin and paclitaxel induced cutaneous MC accumulation in the hindpaw of WT mice, but they triggered distinct MC mediator-release profiles in vivo: oxaliplatin preferentially elevated tryptase, while paclitaxel was associated with greater histamine enrichment. Yet, neither drug directly activate MCs in vitro, as indicated by unchanged β-hexosaminidase release and calcium signaling. Importantly, MrgprB2 KO selectively attenuated oxaliplatin-induced tryptase upregulation and mechanical and cold hypersensitivity in vivo, without affecting paclitaxel-induced histamine changes or pain behavior. Consistently, with these genetic results, osthole selectively attenuated oxaliplatin-induced pain, but not paclitaxel-induced pain in WT mice.
CONCLUSIONS: These findings support a mechanistic dichotomy in CIPN pain, indicating that MrgprB2 contributes selectively to oxaliplatin-induced, but not paclitaxel-induced, CIPN in mice. More broadly, they suggest that CIPN involves mechanistically distinct neuroimmune states depending on the chemotherapeutic class and highlight MrgprB2/X2 as a drug class-selective target for platinum-induced CIPN pain treatment.